Illumina Acquires Myraqa, a Leading IVD and Companion Diagnostic Consulting Firm

  Illumina Acquires Myraqa, a Leading IVD and Companion Diagnostic Consulting
  Firm

             Acquistion Strengthens Illumina’s Clinical Readiness

Business Wire

SAN DIEGO -- July 16, 2014

Illumina, Inc. (NASDAQ:ILMN) today announced that it has acquired Myraqa, a
regulatory and quality consulting firm specializing in IVDs, particularly
companion diagnostics. Led by founder and CEO Mya Thomae, Myraqa focuses on
regulatory strategy and application support, including PMAs, pre-submissions,
IDEs, 510(k)s, de novo 510(k)s, and EU technical files. The acquisition will
bolster Illumina’s in-house capabilities for clinical readiness and help
prepare for its next growth phase in regulated markets.

“Under Mya Thomae, Myraqa is recognized as the leader in regulatory and
quality matters in molecular diagnostics,” said Rick Klausner, M.D., Chief
Medical Officer of Illumina. “With Myraqa, Illumina will continue to pave the
way for the use of genomic technology, including next-generation sequencing,
in regulated markets while also driving standards for use in the clinic. Mya
will lead Illumina’s regulatory strategy and execution, providing us with a
world-class regulatory organization and is part of our commitment to making
Illumina a pre-eminent clinical company.”

“Illumina is at the forefront of driving next-generation sequencing to the
clinic and I look forward to being a key part of this market transformation,”
said Mya Thomae, CEO of Myraqa. “Illumina exemplifies many of the values that
have successfully guided Myraqa and I’m excited for our team to share in this
opportunity to shape the future of medicine.”

As part of Illumina, Myraqa’s team will continue to report to Thomae. Thomae
will report to Illumina’s CMO Dr. Klausner as the Vice President of Regulatory
Affairs.

“We expect Mya and her team to complete existing programs and to continue to
work with selected third-parties on sequencing-based projects,” added Dr.
Klausner.

Myraqa is based in Redwood Shores, California and was founded in 1998. It
comprises leading experts in regulatory, quality, clinical, biostatistics and
development.

The financial impact of this transaction was contemplated in the 2014
financial guidance released on April 22, 2014.

AboutIllumina

Illumina(www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Eric Endicott, 858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.